EYEN Eyenovia Inc.

4.21
-0.33  -7%
Previous Close 4.54
Open 4.6
Price To Book 4.38
Market Cap 71,994,056
Shares 17,100,726
Volume 73,603
Short Ratio
Av. Daily Volume 97,502
Stock charts supplied by TradingView

NewsSee all news

  1. Eyenovia Expands Scientific Advisory Board with Two Experts in Optometry

    NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print

  2. Eyenovia Reports Third Quarter 2019 Financial Results

    NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print

  3. Eyenovia Announces Conference Call and Webcast for Third Quarter 2019 Financial Results

    NEW YORK, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print

  4. Eyenovia Advances MicroLine for the Treatment of Presbyopia Towards Phase III Development and Reprioritizes Late-Stage Ophthalmology Pipeline

    Defers development activities of MicroProst and MicroTears Company to host conference call on Tuesday, October 29, 2019 at 5:00 pm ET NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a

  5. Eyenovia to Participate in Multiple Upcoming Medical Meetings

    NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 enrolment to be completed end of 2020.
MicroPine - CHAPERONE
Myopia
Development to be deferred - noted October 29, 2019.
MicroTears
Dry eye disease
NDA filing due 2020.
MicroStat
Mydriasis - pupil dilation
Development to be deferred - noted October 29, 2019.
MicroProst
Chronic angle closure glaucoma (CACG)
Phase 3 trial to be initiated and completed in 2020.
MicroLine
Presbyopia

Latest News

  1. Eyenovia Expands Scientific Advisory Board with Two Experts in Optometry

    NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print

  2. Eyenovia Reports Third Quarter 2019 Financial Results

    NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print

  3. Eyenovia Announces Conference Call and Webcast for Third Quarter 2019 Financial Results

    NEW YORK, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print

  4. Eyenovia Advances MicroLine for the Treatment of Presbyopia Towards Phase III Development and Reprioritizes Late-Stage Ophthalmology Pipeline

    Defers development activities of MicroProst and MicroTears Company to host conference call on Tuesday, October 29, 2019 at 5:00 pm ET NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a

  5. Eyenovia to Participate in Multiple Upcoming Medical Meetings

    NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print

  6. Eyenovia to Present at Two Upcoming Investor Conferences

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print